MicroRNA‑761 inhibits the metastasis of gastric cancer by negatively regulating Ras and Rab interactor 1

Zhang,Qifu; Sui,Yana; Sui,Xiaomei

doi:10.3892/ol.2019.10645

MicroRNA‑761 inhibits the metastasis of gastric cancer by negatively regulating Ras and Rab interactor 1

Authors:
- Qifu Zhang
- Yana Sui
- Xiaomei Sui
View Affiliations

Affiliations: Radiotherapy Department, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261000, P.R. China, Emergency Department, Weifang Traditional Chinese Hospital, Weifang, Shandong 261000, P.R. China
Published online on: July 22, 2019 https://doi.org/10.3892/ol.2019.10645
Pages: 3097-3103
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC), the second most common malignant cancer worldwide, gives rise to a number of cancer‑associated fatalities annually. Accumulating evidence has shown that microRNAs (miRs) may serve as oncogenes or tumor suppressors in GC development. The aim of this study was to discover the expression, function and mechanism of miR‑761 in GC progression. First, the findings revealed that the expression level of miR‑761 was significantly decreased in GC cell lines and tissues. The functional studies showed that miR‑761 in GC cells inhibited tumor proliferation and metastasis. In the mechanistic study, through an online database search and luciferase assay, Ras and Rab interactor 1 (RIN1), which has been demonstrated as an oncogene in various types of cancer, including GC, was identified as a target of miR‑761. Notably, miR‑761 expression was demonstrated to be negatively correlated with RIN1 mRNA levels in GC tissues. Simultaneously, overexpression of RIN1 partially rescued the inhibitory effect of miR‑761 mimic in the GC cells. The present study provided new insights into the role of miR‑761 in the progression of GC, and implicated the potential application of miR‑761 in GC cell therapy.

View Figures

View References

1	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
2	Choi IJ, Lee JH, Kim YI, Kim CG, Cho SJ, Lee JY, Ryu KW, Nam BH, Kook MC and Kim YW: Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc. 81:333–341 e1. 2015. View Article : Google Scholar : PubMed/NCBI
3	Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, et al: A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 21:68–73. 2018. View Article : Google Scholar : PubMed/NCBI
4	Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 (Suppl 5):v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
5	Valinezhad Orang A, Safaralizadeh R and Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics. 2014:9706072014. View Article : Google Scholar : PubMed/NCBI
6	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yuan HL, Wang T and Zhang KH: MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther. 11:3891–3900. 2018. View Article : Google Scholar : PubMed/NCBI
8	Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T and Yousefi M: MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
9	Li GF, Li L, Yao ZQ and Zhuang SJ: Hsa_circ_ 0007534/miR-761/ZIC5 regulatory loop modulates the proliferation and migration of glioma cells. Biochem Biophys Res Commun. 499:765–771. 2018. View Article : Google Scholar : PubMed/NCBI
10	Cao S, Lin L, Xia X and Wu H: MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1. Oncotarget. 9:321–331. 2017.PubMed/NCBI
11	Guo GC, Wang JX, Han ML, Zhang LP and Li L: microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cell Oncol (Dordr). 40:157–166. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y, Xie H, Zhou L, Zheng S and Wang W: MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. Cancer Sci. 107:424–432. 2016. View Article : Google Scholar : PubMed/NCBI
13	Shi C and Zhang Z: miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma. Tumour Biol. 37:5437–5443. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yan A, Yang C, Chen Z, Li C and Cai L: MiR-761 promotes progression and metastasis of non-small cell lung cancer by targeting ING4 and TIMP2. Cell Physiol Biochem. 37:55–66. 2015. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Feng ZH, Fang Y, Zhao LY, Lu J, Wang YQ, Chen ZH, Huang Y, Wei JH, Liang YP, Cen JJ, et al: RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25. Cancer Sci. 108:1620–1627. 2017. View Article : Google Scholar : PubMed/NCBI
17	Li F, Fang Z, Zhang J, Li C, Liu H, Xia J, Zhu H, Guo C, Qin Z, Li F, et al: Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Res. 26:1149–1164. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liu HY, Wu G, He H, Wang YW, Cheng Y and Liu YF: RIN1 expression in hepatocellular cancer and the affection on prognosis and tumor invasion ability. Zhonghua Wai Ke Za Zhi. 51:1025–1029. 2013.(In Chinese). PubMed/NCBI
19	Fang P, Zhao Z, Tian H and Zhang X: RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma. Tumour Biol. 33:1511–1518. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yu HF, Zhao G, Ge ZJ, Wang DR, Chen J, Zhang Y, Zha TZ, Zhang K, Zhang M, Tan YF, et al: High RIN1 expression is associated with poor prognosis in patients with gastric adenocarcinoma. Tumour Biol. 33:1557–1563. 2012. View Article : Google Scholar : PubMed/NCBI
21	Shan GY, Zhang Z, Chen QG, Yu XY, Liu GB and Kong CZ: Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumour Biol. 33:847–855. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang Q, Gao Y, Tang Y, Ma L, Zhao M and Wang X: Prognostic significance of RIN1 gene expression in human non-small cell lung cancer. Acta Histochem. 114:463–468. 2012. View Article : Google Scholar : PubMed/NCBI